These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 19470335

  • 1. Botulinum toxin for the management of adult patients with upper motor neuron syndrome.
    Esquenazi A, Mayer NH, Elia AE, Albanese A.
    Toxicon; 2009 Oct; 54(5):634-8. PubMed ID: 19470335
    [Abstract] [Full Text] [Related]

  • 2. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: a preliminary analysis of goals and outcomes.
    Ashford S, Turner-Stokes L.
    Disabil Rehabil; 2009 Oct; 31(3):220-6. PubMed ID: 18608366
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: grasp strategies and kinematics of reach-to-grasp movements.
    Bensmail D, Robertson J, Fermanian C, Roby-Brami A.
    Neurorehabil Neural Repair; 2010 Feb; 24(2):141-51. PubMed ID: 19786722
    [Abstract] [Full Text] [Related]

  • 4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB.
    Toxicon; 2013 Jun 01; 67():115-28. PubMed ID: 23220492
    [Abstract] [Full Text] [Related]

  • 5. [Use of botulinum neurotoxin for spasticity].
    Mukai Y, Kaji R.
    Brain Nerve; 2008 Dec 01; 60(12):1421-6. PubMed ID: 19110753
    [Abstract] [Full Text] [Related]

  • 6. [Botulinum toxin injections and hypertonic upper limbs. Which functional results?].
    Ferrapie AL, Vieillart A, Saint-Cast Y, Menei P, Richard I.
    Ann Readapt Med Phys; 2005 May 01; 48(4):172-9. PubMed ID: 15848259
    [Abstract] [Full Text] [Related]

  • 7. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.
    Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C.
    Arch Phys Med Rehabil; 2008 May 01; 89(5):799-806. PubMed ID: 18452724
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements.
    Bensmail D, Robertson JV, Fermanian C, Roby-Brami A.
    Neurorehabil Neural Repair; 2010 May 01; 24(3):273-81. PubMed ID: 20067949
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy.
    Lundy CT, Doherty GM, Fairhurst CB.
    Dev Med Child Neurol; 2009 Sep 01; 51(9):705-10. PubMed ID: 19459910
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.
    Sheean G.
    Drug Saf; 2006 Sep 01; 29(1):31-48. PubMed ID: 16454533
    [Abstract] [Full Text] [Related]

  • 13. Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.
    Hecht MJ, Stolze H, Auf dem Brinke M, Giess R, Treig T, Winterholler M, Wissel J, German Spasticity Education Group.
    Mov Disord; 2008 Jan 30; 23(2):228-33. PubMed ID: 17999430
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.
    Dong Y, Wu T, Hu X, Wang T.
    Eur J Phys Rehabil Med; 2017 Apr 30; 53(2):256-267. PubMed ID: 27834471
    [Abstract] [Full Text] [Related]

  • 15. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 May 06; 70(19):1691-8. PubMed ID: 18458229
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Contralateral weakness following botulinum toxin for poststroke spasticity.
    Thomas AM, Simpson DM.
    Muscle Nerve; 2012 Sep 06; 46(3):443-8. PubMed ID: 22907238
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.